Influential factors in the adherence and abandonment of preventive therapy for latent tuberculosis infection in patients with HIV

Factores influyentes en la adherencia y abandono en la terapia preventiva para la infección por tuberculosis latente en pacientes con VIH

Objective: to describe the factors that influence the lack of adherence to the treatment of the latent tuberculosis infection. Materials and methods: retrospective and descriptive study in people living with the human immunodeficiency virus treated in a health institution of Medellin, Colombia. Results: 45% of patients presented adherence problems such as interruptions less than 30 days or loss of follow-up, the statistical significance (p <0.05) was presented in the variables of adverse effects and adherence to antiretroviral treatment. Conclusion: Adverse effects to treatment and adherence to antiretroviral therapy are associated with problems of adherence to preventive treatment of latent tuberculosis infection.

---

Article visits | PDF visits

---

Downloads

Download data is not yet available.

1. Mindachew M, Deribew A, Tessema F, Biadgilign S. Predictors of adherence to isoniazid preventive therapy among HIV positive adults in Addis Ababa Ethiopia. BMC Public Health 2011; 11:916. DOI: https://doi.org/10.1186/1471-2458-11-916.
2. Parrish NM, Dick JD, Bishai WR. Mechanisms of latency in Mycobacterium tuberculosis. Trends Microbiol 1998; 6(3):107-12.
3. Organización Mundial de la Salud. Directrices sobre la atención de la infección tuberculosa latent. Ginebra: Organización Mundial de la Salud; 2018.
4. Rodríguez J. Tuberculosis latente. Rev Chil Enferm Respir 2012; 28(1):61-8.
5. Barrios-Payán JA, Castañón-Arreola M, Flores-Valdez MA, Hernández-Pando R. Aspectos biológicos, clínicos y epidemiológicos de la tuberculosis latente. Salud Pública Méx 2010; 52(1):70-68.
6. Ayele HT, van Mourik MSM, Debray TPA, Bonten MJM. Isoniazid Prophylactic Therapy for the Prevention of Tuberculosis in HIV Infected Adults: A Systematic Review and Meta-Analysis of Randomized Trials. PLoS ONE 2015; 10(11): e0142290. DOI: 10.1371/journal.pone.0142290.
7. Moro RN, Borisov AS, Saukkonen J, Khan A, Sterling TR, Villarino ME, et al. Factors Associated With Noncompletion of Latent Tuberculosis Infection Treatment: Experience From the PREVENT TB Trial in the United States and Canada. Clin Infect Dis Off Publ Infect Dis Soc Am 2016; 62(11):1390-400. DOI: 10.1093/cid/ciw126.
8. Gust DA, Mosimaneotsile B, Mathebula U, Chingapane B, Gaul Z, Pals SL, et al. Risk factors for non-adherence and loss to follow-up in a three-year clinical trial in Botswana. PloS One 2011; 6(4):e18435. DOI: https://doi.org/10.1371/journal.pone.0018435
9. Domínguez J, Latorre I, Santin M. Diagnosis and therapeutic approach of latent tuberculosis infection. Enferm Infecc Microbiol Clin 2018; 36(5):302-311. DOI: 10.1016/j.eimc.2017.11.014.
10. Machado A, Finkmoore B, Emodi K, Takenami I, Barbosa T, Tavares M, et al. Risk factors for failure to complete a course of latent tuberculosis infection treatment in Salvador, Brazil. Int J Tuberc Lung Dis Off J Int Union Tuberc Lung Dis 2009; 13(6):719-25.
11. Ministerio de Salud y Protección Social. Circular externa N°0007; Colombia; 2015
12. Ayele HT, van Mourik MSM, Bonten MJM. Predictors of adherence to isoniazid preventive therapy in people living with HIV in Ethiopia. Int J Tuberc Lung Dis 2016; 20(10):1342-1347.
13. Szakacs TA, Wilson D, Cameron DW, Clark M, Kocheleff P, Muller FJ, et al. Adherence with isoniazid for prevention of tuberculosis among HIV-infected adults in South Africa. BMC Infect Dis 2006; 6:97.
14. Gust DA, Mosimaneotsile B, Mathebula U, Chingapane B, Gaul Z, Pals SL, et al. Risk factors for non-adherence and loss to follow-up in a three-year clinical trial in Botswana. PloS One 2011; 6(4):e18435. DOI: 10.1371/journal.pone.0018435.
15. Toure S, Kouadio B, Seyler C, Traore M, Dakoury-Dogbo N, Duvignac J, et al. Rapid scaling-up of antiretroviral therapy in 10,000 adults in Côte d’Ivoire: 2-year outcomes and determinants. AIDS Lond Engl 2008; 22(7):873-82. DOI: 10.1097/QAD.0b013e3282f768f8.
16. Kan B, Kalin M, Bruchfeld J. Completing treatment for latent tuberculosis: patient background matters. Int J Tuberc Lung Dis 2013; 17(5):597-602. DOI: 10.5588/ijtld.12.0692.
17. Trajman A, Long R, Zylberberg D, Dion MJ, Al-Otaibi B, Menzies D. Factors associated with treatment adherence in a randomised trial of latent tuberculosis infection treatment. Int J Tuberc Lung Dis 2010; 14(5):551-9.
18. Hirsch-Moverman Y, Colson PW, Bethel J, Franks J, El-Sadr WM. Can a peer-based intervention impact adherence to the treatment of latent tuberculous infection? Int J Tuberc Lung Dis 2013; 17(9):1178-85. DOI: 10.5588/ijtld.12.0823.
19. Parsyan AE, Saukkonen J, Barry MA, Sharnprapai S, Horsburgh CR Jr. Predictors of failure to complete treatment for latent tuberculosis infection. J Infect 2007; 54(3):262-6.
20. Kwara A, Herold JS, Machan JT, Carter EJ. Factors Associated With Failure To Complete Isoniazid Treatment for Latent Tuberculosis Infection in Rhode Island. Chest 2008; 133(4):862-8.
21. Diaz A, Diez M, Bleda MJ, Aldamiz M, Camafort M, Camino X, et al. Eligibility for and outcome of treatment of latent tuberculosis infection in a cohort of HIV-infected people in Spain. BMC Infect Dis 2010; 10:267. DOI: 10.1186/1471-2334-10-267.